MBX Biosciences (NASDAQ:MBX) CEO Steven Hoerter Sells 4,893 Shares of Company Stock

MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) CEO Steven Hoerter sold 4,893 shares of MBX Biosciences stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $54.82, for a total value of $268,234.26. Following the transaction, the chief executive officer owned 78,045 shares in the company, valued at $4,278,426.90. This represents a 5.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

MBX Biosciences Price Performance

NASDAQ:MBX opened at $54.51 on Friday. The business’s fifty day moving average price is $55.89 and its 200 day moving average price is $46.29. MBX Biosciences, Inc. has a 1-year low of $23.07 and a 1-year high of $72.64.

MBX Biosciences (NASDAQ:MBX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.49). Analysts predict that MBX Biosciences, Inc. will post -3.20 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on MBX shares. UBS Group restated a “buy” rating on shares of MBX Biosciences in a report on Monday, September 28th. HC Wainwright assumed coverage on shares of MBX Biosciences in a research report on Thursday. They set a “buy” rating and a $90.00 price objective on the stock. Guggenheim upped their price objective on shares of MBX Biosciences from $88.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Citigroup reiterated a “market outperform” rating on shares of MBX Biosciences in a research report on Tuesday, October 27th. Finally, Truist Financial lifted their target price on shares of MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.30.

View Our Latest Report on MBX

Institutional Investors Weigh In On MBX Biosciences

Large investors have recently bought and sold shares of the business. State of Wyoming bought a new stake in shares of MBX Biosciences during the 2nd quarter worth $58,000. Sterling Capital Management LLC grew its stake in MBX Biosciences by 847.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,033 shares of the company’s stock valued at $61,000 after buying an additional 924 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in MBX Biosciences in the 3rd quarter valued at $144,000. Quantbot Technologies LP bought a new position in MBX Biosciences in the 2nd quarter worth $213,000. Finally, Sei Investments Co. raised its holdings in MBX Biosciences by 17.4% in the 1st quarter. Sei Investments Co. now owns 8,989 shares of the company’s stock worth $268,000 after acquiring an additional 1,332 shares during the period.

MBX Biosciences Company Profile

(Get Free Report)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.

Featured Articles

Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.